Management eines massiven zervikalen Hämatoms nach Anlage eines zentralen Venenkatheters unter Tirofiban

Kasuistiken
  • 50 Downloads

Zusammenfassung

Eine 81-jährige Patientin wurde im infarktbedingten kardiogenen Schock zur Herzkatheteruntersuchung übernommen. In der Koronarangiographie zeigte sich ein Verschluss des Ramus interventricularis anterior. Bei unvollständigem Fluss nach perkutaner Koronarintervention mit Implantation von 3 Koronarstents und erhöhter Thrombogenität erfolgte die Gabe von Tirofiban. Im Rahmen der anschließenden Anlage eines zentralvenösen Venenkatheters (ZVK) via V. jugularis interna kam es zu einer arteriellen Fehlpunktion der A. carotis communis mit der Folge von akuter Dyspnoe und eines hämorrhagischen Schocks bedingt durch ein massives zervikales Hämatom. Obwohl die ZVK-Anlage eine häufig angewandte Intervention in der Intensivmedizin darstellt, birgt der Eingriff dennoch ein gewisses Risiko iatrogener Verletzungen. Die Kenntnis über das Notfallmanagement von ZVK-assoziierten Komplikationen ist daher unabdingbar.

Schlüsselwörter

Zentraler Venenkatheter Kardiogener Schock GP-IIb/IIIa-Antagonisten Arterielle Fehlpunktion Hämorrhagischer Schock 

Management of a massive cervical hematoma after insertion of a central venous catheter under tirofiban

Abstract

An 81-year-old woman with infarct-related cardiogenic shock was admitted to the cardiac catheterization laboratory. Coronary angiography revealed an occlusion of the ramus interventricularis anterior. Due to incomplete flow after the percutaneous coronary intervention with implantation of three coronary stents and high thrombus burden, tirofiban was given as a bail out therapy. A central venous catheter (CVC) aimed at the internal jugular vein was incidentally inserted in the common carotid artery, resulting in acute dyspnea and a hemorrhagic shock due to a massive cervical hematoma. Although the CVC is a frequently used intervention in critical care, the procedure still carries some risks of iatrogenic injury. Knowledge about the emergency management of CVC-associated complications is therefore essential.

Keywords

Central venous line Cardiogenic shock GP IIb/IIIa antagonists Arterial puncture Hemorrhagic shock 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

R. Pfister und G. Michels geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren. Alle Patienten, die über Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben.

Literatur

  1. 1.
    Jankovic RJ, Pavlovic MS, Stojanovic MM et al (2011) Risk factors associated with carotid artery puncture following landmark-guided internal jugular vein cannulation attempts. Med Princ Pract 20:562–566CrossRefPubMedGoogle Scholar
  2. 2.
    Guilbert MC, Elkouri S, Bracco D et al (2008) Arterial trauma during central venous catheter insertion: case series, review and proposed algorithm. J Vasc Surg 48:918–925CrossRefPubMedGoogle Scholar
  3. 3.
    Parienti JJ, Mongardon N, Megarbane B et al (2016) Intravascular complications of central venous catheterization by insertion site. N Engl J Med 373(13):1220–1229CrossRefGoogle Scholar
  4. 4.
    Barsuk JH, Mcgaghie WC, Cohen ER et al (2009) Simulation-based mastery learning reduces complications during central venous catheter insertion in a medical intensive care unit. Crit Care Med 37:2697–2701PubMedGoogle Scholar
  5. 5.
    Karakitsos D, Labropoulos N, De Groot E et al (2006) Real-time ultrasound-guided catheterisation of the internal jugular vein: a prospective comparison with the landmark technique in critical care patients. Crit Care 10:R162CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Lennon M, Zaw NN, Popping DM et al (2012) Procedural complications of central venous catheter insertion. Minerva Anestesiol 78:1234–1240PubMedGoogle Scholar
  7. 7.
    Roffi M, Patrono C, Collet J‑P et al (2016) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 37:267–315CrossRefPubMedGoogle Scholar
  8. 8.
    Ibanez B, James S, Agewall S et al (2017) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J.  https://doi.org/10.1093/eurheartj/ehx393 PubMedGoogle Scholar
  9. 9.
    Coller BS (2001) Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost 86:427–443CrossRefPubMedGoogle Scholar
  10. 10.
    Guo J, Xu M, Xi Y (2012) Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty. Tex Heart Inst J 39:99–103PubMedPubMedCentralGoogle Scholar
  11. 11.
    Durand M, Lecompte T, Hacquard M et al (2008) Heparin-induced thrombocytopenia and cardiopulmonary bypass: anticoagulation with unfractionated heparin and the GPIIb/IIIa inhibitor tirofiban and successful use of rFVIIa for post-protamine bleeding due to persistent platelet blockade. Eur J Cardiothorac Surg 34:687–689CrossRefPubMedGoogle Scholar
  12. 12.
    Stepinska J, Banaszewski M, Konopka A et al (2002) Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban. Thromb Haemost 87:355–356CrossRefPubMedGoogle Scholar
  13. 13.
    Gayet-Ageron A, Prieto-Merino D, Ker K et al (2018) Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients. Lancet 391(10116):125–132CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Shimada YJ, Bansilal S, Wiviott SD et al (2016) Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J 177:1–8CrossRefPubMedGoogle Scholar
  15. 15.
    Yurtdas M, Yaylali YT, Aladag N, Ozdemir M, Atay MH (2014) Acute serious thrombocytopenia associated with intracoronary tirofiban use for primary angioplasty. Case Rep Med 2014:190149CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Graham AS, Ozment C, Tegtmeyer K, Lai S, Braner DA (2007) Central venous catheterization. N Engl J Med 356(21):e21CrossRefPubMedGoogle Scholar
  17. 17.
    Smith RN, Nolan JP (2013) Central venous catheters. BMJ 347:f6570CrossRefPubMedGoogle Scholar
  18. 18.
    Michels G, Kochanek M (2017) Repetitorium Internistische Intensivmedizin, 3. Aufl. Springer, Heidelberg, Berlin, New YorkCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik III für Innere Medizin, HerzzentrumUniversität zu KölnKölnDeutschland

Personalised recommendations